{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:59:50Z","timestamp":1793581190732,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Iron overload and cellular senescence have been implicated in liver fibrosis, but their possible mechanistic connection has not been explored. To address this, we have delved into the role of iron and senescence in an experimental model of chronic liver injury, analyzing whether an iron chelator would prevent liver fibrosis by decreasing hepatocyte senescence. The model of carbon tetrachloride (CCl\n                    <jats:sub>4<\/jats:sub>\n                    ) in mice was used as an experimental model of liver fibrosis. Results demonstrated that during the progression of liver fibrosis, accumulation of iron occurs, concomitant with the appearance of fibrotic areas and cells undergoing senescence. Isolated parenchymal hepatocytes from CCl\n                    <jats:sub>4<\/jats:sub>\n                    -treated mice present a gene transcriptomic signature compatible with iron accumulation and senescence, which correlates with induction of Reactive Oxygen Species (ROS)-related genes, activation of the Transforming Growth Factor-beta (TGF-\u03b2) pathway and inhibition of oxidative metabolism. Analysis of the iron-related gene signature in a published single-cell RNA-seq dataset from CCl\n                    <jats:sub>4<\/jats:sub>\n                    -treated livers showed iron accumulation correlating with senescence in other non-parenchymal liver cells. Treatment with deferiprone, an iron chelator, attenuated iron accumulation, fibrosis and senescence, concomitant with relevant changes in the senescent-associated secretome (SASP), which switched toward a more anti-inflammatory profile of cytokines. In vitro experiments in human hepatocyte HH4 cells demonstrated that iron accumulates in response to a senescence-inducing reagent, doxorubicin, being deferiprone able to prevent senescence and SASP, attenuating growth arrest and cell death. However, deferiprone did not significantly affect senescence induced by two different agents (doxorubicin and deoxycholic acid) or activation markers in human hepatic stellate LX-2 cells. Transcriptomic data from patients with different etiologies demonstrated the relevance of iron accumulation in the progression of liver chronic damage and fibrosis, correlating with a SASP-related gene signature and pivotal hallmarks of fibrotic changes. Altogether, our study establishes iron accumulation as a clinically exploitable driver to attenuate pathological senescence in hepatocytes.\n                  <\/jats:p>","DOI":"10.1038\/s41419-024-07063-0","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T09:44:01Z","timestamp":1726652641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression"],"prefix":"10.1038","volume":"15","author":[{"given":"Josep","family":"Amengual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5090-2913","authenticated-orcid":false,"given":"Ania","family":"Alay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-6962","authenticated-orcid":false,"given":"Javier","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Gonzalez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Bertran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2128-2479","authenticated-orcid":false,"given":"Mate","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-9312","authenticated-orcid":false,"given":"Manuel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6446-9911","authenticated-orcid":false,"given":"Mar\u00eda Luz","family":"Mart\u00ednez-Chantar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-8440","authenticated-orcid":false,"given":"Isabel","family":"Fabregat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"7063_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"7063_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/01.LAB.0000069036.63405.5C","volume":"83","author":"A Canbay","year":"2003","unstructured":"Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003;83:655\u201363.","journal-title":"Lab Invest."},{"key":"7063_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20:633\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"7063_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"7063_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcmgh.2023.09.008","volume":"17","author":"HY Kim","year":"2024","unstructured":"Kim HY, Sakane S, Eguileor A, Carvalho Gontijo Weber R, Lee W, Liu X, et al. The origin and fate of liver myofibroblasts. Cell Mol Gastroenterol Hepatol. 2024;17:93\u2013106.","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"7063_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-0040-1722262","volume":"41","author":"S Ferreira-Gonzalez","year":"2021","unstructured":"Ferreira-Gonzalez S, Rodrigo-Torres D, Gadd VL, Forbes SJ. Cellular senescence in liver disease and regeneration. Semin Liver Dis. 2021;41:50\u201366.","journal-title":"Semin Liver Dis."},{"key":"7063_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112689","volume":"405","author":"H Yu","year":"2021","unstructured":"Yu H, Jiang X, Dong F, Zhang F, Ji X, Xue M, et al. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. Exp Cell Res. 2021;405:112689.","journal-title":"Exp Cell Res."},{"key":"7063_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3390\/cells11142221","volume":"11","author":"P Wijayasiri","year":"2022","unstructured":"Wijayasiri P, Astbury S, Kaye P, Oakley F, Alexander GJ, Kendall TJ, et al. Role of hepatocyte senescence in the activation of hepatic stellate cells and liver fibrosis progression. Cells. 2022;11:2221.","journal-title":"Cells."},{"key":"7063_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1230","volume":"10","author":"TG Bird","year":"2018","unstructured":"Bird TG, Muller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, et al. TGF\u03b2 inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. Sci Transl Med. 2018;10:eaan1230.","journal-title":"Sci Transl Med."},{"key":"7063_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1101\/gad.332643.119","volume":"34","author":"B Ritschka","year":"2020","unstructured":"Ritschka B, Knauer-Meyer T, Goncalves DS, Mas A, Plassat JL, Durik M, et al. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice. Genes Dev. 2020;34:489\u201394.","journal-title":"Genes Dev."},{"key":"7063_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","volume":"134","author":"V Krizhanovsky","year":"2008","unstructured":"Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134:657\u201367.","journal-title":"Cell."},{"key":"7063_CR12","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/hep4.2012","volume":"6","author":"CC Hsu","year":"2022","unstructured":"Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Iron overload disorders. Hepatol Commun. 2022;6:1842\u201354.","journal-title":"Hepatol Commun."},{"key":"7063_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jhep.2011.05.008","volume":"55","author":"P Dongiovanni","year":"2011","unstructured":"Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol. 2011;55:920\u201332.","journal-title":"J Hepatol."},{"key":"7063_CR14","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ajpath.2022.08.010","volume":"193","author":"N Ali","year":"2023","unstructured":"Ali N, Ferrao K, Mehta KJ. Liver iron loading in alcohol-associated liver disease. Am J Pathol. 2023;193:1427\u201339.","journal-title":"Am J Pathol."},{"key":"7063_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jhep.2006.09.021","volume":"46","author":"D Guyader","year":"2007","unstructured":"Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol. 2007;46:587\u201395.","journal-title":"J Hepatol."},{"key":"7063_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jhep.2014.04.034","volume":"61","author":"M Lunova","year":"2014","unstructured":"Lunova M, Goehring C, Kuscuoglu D, Mueller K, Chen Y, Walther P, et al. Hepcidin knockout mice fed with iron-rich diet develop chronic liver injury and liver fibrosis due to lysosomal iron overload. J Hepatol. 2014;61:633\u201341.","journal-title":"J Hepatol."},{"key":"7063_CR17","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/hep.31900","volume":"74","author":"S Colucci","year":"2021","unstructured":"Colucci S, Altamura S, Marques O, Dropmann A, Horvat NK, Mudder K, et al. Liver sinusoidal endothelial cells suppress bone morphogenetic protein 2 production in response to TGF\u03b2 pathway activation. Hepatology. 2021;74:2186\u2013200.","journal-title":"Hepatology."},{"key":"7063_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3748\/wjg.v25.i5.521","volume":"25","author":"KJ Mehta","year":"2019","unstructured":"Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: mechanistic and clinical aspects. World J Gastroenterol. 2019;25:521\u201338.","journal-title":"World J Gastroenterol."},{"key":"7063_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/s42255-023-00928-2","volume":"5","author":"M Maus","year":"2023","unstructured":"Maus M, Lopez-Polo V, Mateo L, Lafarga M, Aguilera M, De Lama E, et al. Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype. Nat Metab. 2023;5:2111\u201330.","journal-title":"Nat Metab."},{"key":"7063_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/hep.26706","volume":"59","author":"MJ Wood","year":"2014","unstructured":"Wood MJ, Gadd VL, Powell LW, Ramm GA, Clouston AD. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology. 2014;59:848\u201357.","journal-title":"Hepatology."},{"key":"7063_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep."},{"key":"7063_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1006\/bbrc.1996.0698","volume":"222","author":"CY Kao","year":"1996","unstructured":"Kao CY, Factor VM, Thorgeirsson SS. Reduced growth capacity of hepatocytes from c-myc and c-myc\/TGF-alpha transgenic mice in primary culture. Biochem Biophys Res Commun. 1996;222:64\u201370.","journal-title":"Biochem Biophys Res Commun."},{"key":"7063_CR23","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884\u2013i90.","journal-title":"Bioinformatics."},{"key":"7063_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics."},{"key":"7063_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics."},{"key":"7063_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul D, Kosinsky RL, Atkinson EJ, Doolittle ML, Zhang X, LeBrasseur NK, et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat Commun. 2022;13:4827.","journal-title":"Nat Commun."},{"key":"7063_CR27","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2353\/ajpath.2007.070413","volume":"171","author":"W Tang","year":"2007","unstructured":"Tang W, Lazaro CA, Campbell JS, Parks WT, Katze MG, Fausto N. Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame. Am J Pathol. 2007;171:1831\u201346.","journal-title":"Am J Pathol."},{"key":"7063_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102818","volume":"65","author":"R Espinosa-Sotelo","year":"2023","unstructured":"Espinosa-Sotelo R, Fuste NP, Penuelas-Haro I, Alay A, Pons G, Almodovar X, et al. Dissecting the role of the NADPH oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma. Redox Biol. 2023;65:102818.","journal-title":"Redox Biol."},{"key":"7063_CR29","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00204-016-1761-4","volume":"90","author":"P Godoy","year":"2016","unstructured":"Godoy P, Widera A, Schmidt-Heck W, Campos G, Meyer C, Cadenas C, et al. Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue. Arch Toxicol. 2016;90:2513\u201329.","journal-title":"Arch Toxicol."},{"key":"7063_CR30","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1002\/hep.31987","volume":"74","author":"W Yang","year":"2021","unstructured":"Yang W, He H, Wang T, Su N, Zhang F, Jiang K, et al. Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology. 2021;74:2774\u201390.","journal-title":"Hepatology."},{"key":"7063_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05855-4","volume":"14","author":"S Hammad","year":"2023","unstructured":"Hammad S, Ogris C, Othman A, Erdoesi P, Schmidt-Heck W, Biermayer I, et al. Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation. Cell Death Dis. 2023;14:414.","journal-title":"Cell Death Dis."},{"key":"7063_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1040031","volume":"13","author":"AS Kurt","year":"2022","unstructured":"Kurt AS, Strobl K, Ruiz P, Osborn G, Chester T, Dawson L, et al. IL-2 availability regulates the tissue specific phenotype of murine intra-hepatic Tregs. Front Immunol. 2022;13:1040031.","journal-title":"Front Immunol."},{"key":"7063_CR33","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s00432-020-03374-9","volume":"146","author":"PT Nguyen","year":"2020","unstructured":"Nguyen PT, Kanno K, Pham QT, Kikuchi Y, Kakimoto M, Kobayashi T, et al. Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146:3255\u201368.","journal-title":"J Cancer Res Clin Oncol."},{"key":"7063_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo4474","volume":"14","author":"N Fujiwara","year":"2022","unstructured":"Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, et al. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med. 2022;14:eabo4474.","journal-title":"Sci Transl Med."},{"key":"7063_CR35","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1053\/j.gastro.2017.10.048","volume":"154","author":"E Trepo","year":"2018","unstructured":"Trepo E, Goossens N, Fujiwara N, Song WM, Colaprico A, Marot A, et al. Combination of gene expression signature and model for end-stage liver disease score predicts survival of patients with severe alcoholic hepatitis. Gastroenterology. 2018;154:965\u201375.","journal-title":"Gastroenterology."},{"key":"7063_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coph.2019.09.006","volume":"49","author":"S Lemoinne","year":"2019","unstructured":"Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol. 2019;49:60\u201370.","journal-title":"Curr Opin Pharmacol."},{"key":"7063_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/jpps.2023.11808","volume":"26","author":"OS Mohammed","year":"2023","unstructured":"Mohammed OS, Attia HG, Mohamed B, Elbaset MA, Fayed HM. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. J Pharm Pharm Sci. 2023;26:11808.","journal-title":"J Pharm Pharm Sci."},{"key":"7063_CR38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.32285","volume":"75","author":"SL Friedman","year":"2022","unstructured":"Friedman SL, Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology. 2022;75:473\u201388.","journal-title":"Hepatology."},{"key":"7063_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41575-024-00913-4","volume":"21","author":"D Sanfeliu-Redondo","year":"2024","unstructured":"Sanfeliu-Redondo D, Gibert-Ramos A, Gracia-Sancho J. Cell senescence in liver diseases: pathological mechanism and theranostic opportunity. Nat Rev Gastroenterol Hepatol. 2024;21:477\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"7063_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bcp.2015.09.001","volume":"98","author":"SF Darwish","year":"2015","unstructured":"Darwish SF, El-Bakly WM, El-Naga RN, Awad AS, El-Demerdash E. Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: impact on interferon therapy. Biochem Pharmacol. 2015;98:231\u201342.","journal-title":"Biochem Pharmacol."},{"key":"7063_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/1440-1681.12591","volume":"43","author":"A Mohammed","year":"2016","unstructured":"Mohammed A, Abd Al Haleem EN, El-Bakly WM, El-Demerdash E. Deferoxamine alleviates liver fibrosis induced by CCl4 in rats. Clin Exp Pharm Physiol. 2016;43:760\u20138.","journal-title":"Clin Exp Pharm Physiol."},{"key":"7063_CR42","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1101\/gad.343129.120","volume":"34","author":"J Birch","year":"2020","unstructured":"Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34:1565\u201376.","journal-title":"Genes Dev."},{"key":"7063_CR43","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood-2003-07-2378","volume":"103","author":"AS Zhang","year":"2004","unstructured":"Zhang AS, Xiong S, Tsukamoto H, Enns CA. Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood. 2004;103:1509\u201314.","journal-title":"Blood."},{"key":"7063_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","volume":"59","author":"C Brenner","year":"2013","unstructured":"Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583\u201394.","journal-title":"J Hepatol."},{"key":"7063_CR45","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/ncb3225","volume":"17","author":"N Herranz","year":"2015","unstructured":"Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, Hanley CJ, et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol. 2015;17:1205\u201317.","journal-title":"Nat Cell Biol."},{"key":"7063_CR46","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ncb3195","volume":"17","author":"RM Laberge","year":"2015","unstructured":"Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049\u201361.","journal-title":"Nat Cell Biol."},{"key":"7063_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2021.111572","volume":"199","author":"M Zhang","year":"2021","unstructured":"Zhang M, Serna-Salas S, Damba T, Borghesan M, Demaria M, Moshage H. Hepatic stellate cell senescence in liver fibrosis: characteristics, mechanisms and perspectives. Mech Ageing Dev. 2021;199:111572.","journal-title":"Mech Ageing Dev."},{"key":"7063_CR48","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1097\/HEP.0000000000000401","volume":"78","author":"R Maeso-Diaz","year":"2023","unstructured":"Maeso-Diaz R, Du K, Pan C, Guy CD, Oh SH, Chen T, et al. Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression. Hepatology. 2023;78:1209\u201322.","journal-title":"Hepatology."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07063-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:58:12Z","timestamp":1726739892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07063-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["7063"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-07063-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4376183\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS is shareholder of Senolytic Therapeutics, Inc., Life Biosciences, Inc., Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The procedure complied with the EU Directive 2010\/63\/UE for animal experiments and the institution\u2019s guidelines and was approved by the General Direction of Environment and Biodiversity, Government of Catalonia (#4589) and the Ethical Committee for Animal Experimentation at IDIBELL, with the number EST-FOR-90.01. We have followed the 3R recommendations: Replacement, Reduction and Refinement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"680"}}